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Galectin-1 (Gal-1) exerts immune-regulatory and anti-inflammatory actions in animal
models of acute and chronic inflammation. Its release into the extracellular milieu often
correlates with the peak of inflammation suggesting that it may serve a pro-resolving
function. Gal-1 is reported to inhibit neutrophil recruitment and induce surface exposure
of phosphatidylserine (PS), an “eat me” signal on the surface of neutrophils, yet its role
in resolution remains to be fully elucidated. We hypothesized that the anti-inflammatory
and pro-resolving properties of Gal-1 are mediated through its ability to inhibit neutrophil
recruitment and potentiate neutrophil clearance. To investigate this, a murine model
of self-resolving inflammation was utilized to uncover the role of both the endogenous
and exogenous protein using Gal-1 null mice and recombinant protein, respectively. We
found that peritoneal macrophages express increased Gal-1 during the resolution phase
and enhanced neutrophil recruitment occurs in the early phases of zymosan peritonitis
in Gal-1 null mice compared to their wild-type (WT) counterparts. Administration of
recombinant Gal-1 following the peak of inflammation led to reduced neutrophil numbers
at 24 and 48 h, shortening the resolution interval from 39 to 14 h. Gal-1 treatment also
enhanced neutrophil apoptosis, indicating a pro-resolving action. Together these results
indicate an important role for Gal-1 in the timely resolution of acute inflammation.
Keywords: galectin-1, leukocytes, inflammation, resolution, apoptosis
INTRODUCTION
Neutrophil trafficking to the site of inflammation is essential for the clearance of infection and
repair of injured tissue. However, excessive inflammation is deleterious to the host and can
result in damage to healthy tissue and the development of chronic inflammatory pathologies
such as rheumatoid arthritis and atherosclerosis (Nathan and Ding, 2010; Perretti et al., 2017;
Kasikara et al., 2018). It is now widely accepted that the resolution of inflammation is an active
process, driven by the generation of pro-resolving mediators such as resolvins and Annexin A1
by infiltrated neutrophils (Sugimoto et al., 2019). These mediators promote resolution through the
inhibition of neutrophil trafficking, induction of neutrophil apoptosis, and promotion of neutrophil
clearance through efferocytosis, processes that are key to the restoration of tissue homeostasis
(Norling and Perretti, 2013).
Galectin-1 (Gal-1) is the prototype member of the galectin family, which shares a
specificity for β-galactoside containing proteins and lipids. Several galectins have been ascribed
immunomodulatory functions, with Gal-1 generally regarded as anti-inflammatory due to its
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inhibitory effects on neutrophil and T cell trafficking and
induction of T cell apoptosis (He and Baum, 2006; Toscano
et al., 2007; Cooper et al., 2008; Norling et al., 2008; Earl et al.,
2010). Evidence is emerging that Gal-1 may also have pro-
resolving actions: expression often peaks at the height of the
inflammatory response (Ilarregui et al., 2009; Iqbal et al., 2011;
Starossom et al., 2012) and Gal-1 was identified in resolving
exudates of mice in a model of peritonitis and was downregulated
by the resolution-toxic anesthetic lidocaine (Chiang et al., 2008).
Current findings suggest that Gal-1 links the innate and adaptive
immune systems as differentiation of dendritic cells in a Gal-1
rich environment leads to enhanced regulatory functions and
suppression of autoimmune disease progression (Ilarregui et al.,
2009). However, more recent evidence has expanded the pro-
resolving potential of Gal-1 to cells of the innate immune system.
Gal-1 has been shown to induce 12/15-lipoxygenase expression
in macrophages, switching them to a pro-resolving phenotype
(Rostoker et al., 2013). A potential role for Gal-1 in neutrophil
clearance has also been suggested due to its ability to induce
phosphatidylserine (PS) exposure on the surface of neutrophils
in vitro (Stowell et al., 2007); however, evidence of this in vivo is
currently lacking.
In this study, we challenge the hypothesis that alongside its
recognized anti-inflammatory actions, Gal-1 also possesses pro-
resolving properties through its actions on neutrophil trafficking
and lifespan. Using a well-characterized model of zymosan-
induced peritonitis, we demonstrate that in the absence of Gal-1
there is increased neutrophil recruitment to the peritoneal cavity,
while administration of recombinant Gal-1 after the peak of
inflammation induces neutrophil apoptosis and clearance.
MATERIALS AND METHODS
Galectin-1
Recombinant Human Gal-1 (hrGal-1) was provided by
GalPharma (Takamatsu, Kagawa, Japan). The recombinant
protein is a cysteine-less mutant with all cysteine residues
substituted with serine residues, which is resistant to
oxidation while retaining all known activities of native Gal-1
(Nishi et al., 2008).
Ethics and Regulations
Experiments performed in vivo adhered to Home Office
regulations (Scientific Procedures Act, 1986) and were
additionally approved under the guidelines set down by the
Ethical Committee for the Use of Animals, Barts and The
London School of Medicine. Additionally, protocols under
the supervision of the above were accomplished baring careful
consideration to the principles set out by the National Centre
for Replacement Refinement and Reduction of Animals in
Research (NC3Rs).
Mice
Male wild-type (WT) C57/BL6 mice were purchased from
Charles River (Kent, United Kingdom). Original breeding
pairs of Gal-1 knockout (KO) mice (Lgals1 null) animals
were generously provided by the Consortium for Functional
Glycomics1 and were bred and housed at Charles River (Kent,
United Kingdom). Where required WT and KO mice were both
age and sex-matched. Mice were housed within individually
ventilated cages (IVCs), a maximum of six mice per cage in a
facility with a 12 h light–dark cycle and ad libitum feeding of a
standard laboratory chow diet and water.
Zymosan-Induced Peritonitis Model
Zymosan-induced peritonitis was performed with Gal-1 KO mice
and WT counterparts or with WT mice administered hrGal-
1 (10 µg). Mice aged 6–8 weeks (n = 3–8) were administered
zymosan [1 mg in 500 µl Dulbecco’s phosphate buffered saline
(DPBS+/+)] by intraperitoneal (i.p) injection at the 0 h time
point. Mice treated with hrGal-1 were given a dose of 10 µg or
vehicle (200 µl DPBS+/+) only control i.p at 8 h post-zymosan
(during the peak phase of response). Mice were sacrificed at
the indicated time points. Peritoneal cavities were lavaged with
ice cold DPBS−/− containing 2 mM EDTA. Total cell numbers
in the peritoneum were quantified by cell counts using Turk’s
Solution. Cell free lavage fluid was retained for analysis of Gal-
1 or inflammatory cytokine levels by ELISA (R&D systems,
Abingdon, United Kingdom, and Labospace Milan, respectively).
For ex vivo apoptosis experiments, mice were treated with hrGal-
1 at 2 h and lavaged at 6 h, cells from 1 ml peritoneal exudate were
then resuspended in RPMI + 0.5% bovine serum albumin (BSA)
and incubated for 20h at 37◦C in 5% CO2 prior to analysis.
Flow Cytometry
Differential cell counts in the peritoneal cavity as well as
intracellular Gal-1 levels were assessed by flow cytometry.
Leukocyte infiltrate was quantified using CD45+ cells as the
parent population and the subsequent percentage of positive
cells by biomarker as follows. Immune cells were labeled with
the following panel of fluorescently conjugated antibodies: CD45
PerCP (clone 30-F11, Biolegend), F4/80 BV650 (clone BM8,
Biolegend) or F4/80 APC (clone BM8, eBioscience), Ly6G PE
(clone 1A8, BD Pharmingen), 7/4 FITC (clone 7/4, Abcam),
CD11b BV785 (clone M1/70, Biolegend) and SiglecF (clone
ES22-10D8, Mitenyl Biotech). In some instances, Ly6C PerCP-
Cy5.5 (clone HK1.4, eBioscience) was used. Following antibody
incubations, cells were washed twice with FACS buffer before
fixation in 1% paraformaldehyde (PFA) solution.
For Gal-1 expression cells were stained as above for cell
specific markers (Ly6C, Ly6G, and F4/80) and then fixed
and permeabilized with BD fixation and permeabilization
buffer before addition of anti-Gal-1 antibody (polyclonal,
R&D systems) followed by AF488 anti-goat IgG (polyclonal,
Invitrogen) secondary antibody to assess Gal-1 levels. In all
cases, antibodies or relevant isotype controls were incubated for
a minimum of 30 min at 4◦C prior to analysis on a BD LSR
Fortessa (BDbiosciences) and analyzed post acquisition using
FlowJo (v10) software.
For in vivo neutrophil apoptosis, the peritoneal exudate was
analyzed immediately post collection. Pelleted cells from 200 µl
1http://www.functionalglycomics.org
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peritoneal exudate were stained with Ly6G (as above). Cells were
washed twice, followed by the addition of AnnexinV FITC (BD
Pharmingen) and Zombie NIR (Biolegend) in AnnexinV binding
buffer (BD Pharmingen). Cells were resuspended, covered, and
incubated [15 min, at room temperature (RT)]. AnnexinV
binding buffer was added to each sample and cells were analyzed
immediately by flow cytometry. Quadrant gating was applied to
determine viable (AnxV−NIR−), early apoptotic (AnxV+NIR−),
late apoptotic (AnxV+NIR+), and necrotic (AnxV−NIR+)
neutrophil populations.
Statistical Analysis
Data are expressed as mean ± SEM. Comparisons were analyzed
for statistical significance. GraphPad Prism (v7) software was
used for all analyses and a P ≤ 0.05 was considered as statistically
significant. Levels of Gal-1 profiled across time (0, 4, 24, and
48 h) were analyzed using a one-way ANOVA with Tukey’s
multiple comparisons test. Leukocyte numbers profiled across
time (2, 6, 24, and 48 h) were analyzed using a two-way
repeated measures ANOVA with Sidak’s multiple comparisons
test. Leukocyte numbers at a single time point (24 h) and
percentage of neutrophils in each quadrant for apoptosis were
analyzed using an unpaired t-test.
RESULTS
Macrophages Are a Source of Gal-1 in
the Peritoneal Cavity
Given that reports in the literature indicate that Gal-1 levels
typically peak at the height of inflammation, we initially sought
to characterize endogenous expression of Gal-1 over the course
of a self-limiting model of zymosan peritonitis in WT mice.
Levels were assessed in both the exudate and the immune cells
(monocytes/macrophages and neutrophils) within the cavity.
Surprisingly, Gal-1 was readily detected in the peritoneal cavity
of naive mice (Figure 1A); however, levels were comparatively
low in the resident macrophage population at this time point
(Figure 1B) suggesting a non-immune cell source of the protein
in naive mice. Levels of Gal-1 within the exudate decreased
following the onset of inflammation with around a 50% reduction
at 24 h post-zymosan. A second peak was observed at 48 h post-
zymosan (Figure 1A), which correlated with increased levels in
the monocytes/macrophages (Ly6C+, F4/80+) (Figure 1B). Gal-
1 expression was negligible in the neutrophil (Ly6G+) population
(data not shown).
Leukocyte Recruitment Is Enhanced in
Gal-1 KO Mice
Given the increased levels of Gal-1 in the peritoneal cavity
during the resolution phase and its expression in the macrophage
population within the cavity, we next sought to determine
whether the absence of Gal-1 would modulate the inflammatory
profile induced by zymosan by utilizing Gal-1 KO mice. In WT
mice, there was a sharp and significant increase in leukocyte
influx into the peritoneal cavity from 2 to 6 h as expected,
FIGURE 1 | Macrophages are a source of Gal-1 in the peritoneal cavity.
Peritoneal lavages were performed on C57/Bl6 naive mice (0 h) or 4, 24, and
48 h following administration of zymosan (1mg in 500 µl DPBS+/+ i.p.) and
cell free supernatants were assayed for Gal-1 concentration by ELISA (A).
Total Gal-1 levels were assessed in permeabilized monocytes/macrophages
(identified using Ly6C+, F4/80+) by flow cytometry (B). Statistical analysis
was performed using a one-way ANOVA with Tukey’s multiple comparisons
test, results are displayed as mean ± SEM, and in all cases, significant results
are considered as *P < 0.05, with ***P < 0.0005 and ****P < 0.0001. n = 3–4
mice per group.
followed by a decline at 24 h. A biphasic response was observed
with a second increase in total leukocyte number at 48 h, as shown
in Figure 2A. Leukocyte recruitment in Gal-1 KO mice mirrored
that observed in WT mice in terms of the temporal nature of the
response; however, significantly more leukocytes migrated into
the peritoneal cavities of Gal-1 KO mice compared to WT at the
peak of the inflammatory response (6 h time point).
Further analysis of leukocyte subtypes identified neutrophils
(7/4+Ly6G+) as the predominant cell type from 2 h onward,
with a decline in number observed at 24 h. While this trend
was observed in both genotypes, significantly more neutrophils
trafficked to the peritoneal cavity of Gal-1 KO mice, compared to
WT at the 6 h time point as shown in Figure 2B.
Monocyte (7/4+Ly6G−) numbers displayed a bell-shaped
trend (Figure 2C) with low numbers at 2 h, a respective rise
at 6 and 24 h followed by a decline at 48 h in WT mice. No
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FIGURE 2 | Leukocyte recruitment is enhanced in Gal-1 KO mice. Mice received zymosan (1 mg in 500 µl DPBS+/+ i.p.) and peritoneal lavage was performed at 2,
6, 24, and 48 h. Total cell counts were performed (A) and the number of neutrophils (7/4+Ly6G+) (B), inflammatory monocytes (7/4+Ly6G−) (C), eosinophils (Siglec
F+) (D), macrophages (F4/80+) (E), mature macrophages (F4/80+CD11bhigh) (F), and resolving macrophages (F4/80+CD11blow) (G) were identified by flow
cytometry. Representative flow cytometry plots are shown for each subset. Statistical analysis was performed using a two-way ANOVA with Sidak’s multiple
comparisons test, results are displayed as mean ± SEM, and in all cases, significant results are considered as P < 0.05. n = 3–8 mice per group.
differences were observed between the genotypes. Eosinophil
(Siglec F+) numbers rose sharply at 48h post-zymosan, indicative
of their pro-resolving phenotype (Yamada et al., 2011), with
no significant differences between genotypes (Figure 2D). In
WT mice, macrophage (F4/80+) numbers were lowest at 2 h,
increased from 2 to 6 h and remained unchanged at 24 h
before rising sharply at 48 h (Figure 2E). At early time points,
there was no significant difference between macrophage numbers
in the cavities of Gal-1 KO mice compared to WT; however,
significantly more macrophages were present in Gal-1 KO mice
at 48 h. Macrophage phenotype was also assessed and while there
were no significant differences between genotypes in the number
of mature macrophages (F4/80+CD11bhigh), significantly more
resolving macrophages (F4/80+CD11blow) were present within
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the cavities of Gal-1 KO mice at 48 h compared to their WT
counterparts (Figures 2F,G).
Along with increased neutrophil recruitment in Gal-1 KO
mice, we also detected significant increases in the pro-
inflammatory cytokine IL-6 as well as the pro-angiogenic growth
factor VEGF in KO mice, with a trend toward increased levels
of the chemokines CCL2, CCL3, and CXCL1 and the pro-
inflammatory cytokine TNF-α (Supplementary Figures S1A–L).
hrGal-1 Administration Following the
Peak of Inflammation Promotes
Neutrophil Clearance
Given the enhanced neutrophil recruitment observed in Gal-
1 KO mice, we next addressed whether Gal-1 is able to
drive resolution when administered following the peak of an
inflammatory response. To this end, hrGal-1 was administered
i.p. at 8 h post-zymosan, a time point where neutrophil
trafficking will have peaked in this model. Administration
of hrGal-1 at this time point resulted in significantly fewer
leukocytes being recovered 16 h later (24 h time point)
compared to those recovered from vehicle treated mice
(Figure 3A). As shown in Figures 3B–G, further analysis of
the individual leukocyte subtypes indicated that there was a
trend toward an all-round decrease in the numbers of all
leukocyte subsets analyzed in the cavities of mice treated
with hrGal-1 (a trend that was also observed at 48 h, see
Supplementary Table S1). Significant reductions in the numbers
of neutrophils (7/4+Ly6G+; Figure 3B), eosinophils (SiglecF+;
Figure 3D), and resolving macrophages (F4/80+CD11blow;
Figure 3G) were observed.
Neutrophils that were collected from the peritoneal cavity at
24 h post-zymosan injection were further assessed for apoptosis.
The majority of neutrophils were viable (70.69 ± 5.21%),
presumably as a result of the rapid clearance of apoptotic cells.
Importantly, significantly fewer viable cells were detected within
the peritoneal cavities of mice treated with hrGal-1 compared to
vehicle (Figure 3H), and a significant increase in the percentage
of early apoptotic neutrophils (AnxV+/PI−) was observed. The
percentage of late apoptotic cells was minimal in both genotypes
again presumably due to their clearance, with negligible numbers
of necrotic neutrophils detected.
To further address the effect of Gal-1 on the apoptotic process,
hrGal-1 was administered during the initial recruitment phase
(2 h) and peritoneal lavages performed at 6 h post-zymosan.
Cells were then incubated in vitro overnight to assess apoptosis.
Here we found that ex vivo late apoptosis of neutrophils was
significantly increased following exposure to Gal-1 (as illustrated
in Supplementary Figure S2).
hrGal-1 Administration Following the
Peak of Inflammation Shortened the
Resolution Interval
In order to quantitate the pro-resolving actions of Gal-1,
resolution indices were calculated. These are widely utilized to
identify mediators that stimulate, as well as those that disrupt or
delay resolution (Bannenberg et al., 2005; Schwab et al., 2007;
Navarro-Xavier et al., 2010). Parameters calculated included
the amplitude and duration of the inflammatory response by
monitoring the maximum neutrophil infiltrate (Tmax), when a
50% loss in neutrophil numbers occurred (T50) and the resolution
interval (Ri; time from Tmax to T50). Treatment with hrGal-1
shortened the resolution interval from 39 h observed in vehicle
treated mice to 14 h, indicating that Gal-1 accelerated neutrophil
clearance from the peritoneal cavity (Figure 4).
DISCUSSION
Leukocyte recruitment is an integral component of the
inflammatory response, whereby a mass migration of cells
through the vasculature toward the site of inflammation occurs.
In this context, it is well established that neutrophils are
the primary leukocyte subset mobilized. While neutrophil
recruitment is critical for a successful inflammatory response, the
temporal and spatial confinement of the neutrophilic infiltrate
is crucial for resolution. Apoptosis is a critical step in paving
the way for successful resolution of acute inflammation, where
apoptotic neutrophils play an essential role in reprogramming
macrophages toward a pro-resolving state (Fredman et al., 2012).
Our findings suggest that Gal-1 should be included in the
expanding list of pro-resolving molecules.
Gal-1 was readily detectable in peritoneal lavage fluid, with
the highest levels detected at 0 and 48 h, suggesting levels are
highest in the absence of inflammation and during resolution.
Macrophages have previously been identified as a source of Gal-
1, with levels highest in M2 macrophages in the peritoneal cavity
(Rabinovich et al., 1996; Fredman et al., 2012), which correlates
with the significant expression observed in macrophages at 48 h
in this current study.
Our data indicate the effects of Gal-1 are multi-faceted, with
neutrophil trafficking and clearance impacted by either the lack
of, or addition of excess (exogenous) Gal-1. Neutrophil trafficking
is significantly enhanced in the absence of Gal-1, a result that
corroborates with the increased leukocyte emigration observed
in the microcirculation of Gal-1 KO mice (Cooper et al., 2008)
and corresponds with reports in the literature of an inhibitory
role for Gal-1 on neutrophil recruitment (Iqbal et al., 2011). In
line with a heightened inflammatory response in the absence of
Gal-1, IL-6 and VEGF levels were also significantly increased in
Gal-1 KO mice. IL-6 is a pleiotropic cytokine involved in the
acute phase response and its inhibition has been shown to reduce
the inflammatory response in a model of zymosan peritonitis
(Cuzzocrea et al., 1999) while VEGF has been shown to induce
rapid recruitment of neutrophils in vivo (Massena et al., 2015).
The majority of studies indicating an effect of Gal-1 on
neutrophil trafficking have focused on the actions of the
exogenous protein (La et al., 2003). Indeed, in a previous
study from our laboratory, administration of hrGal-1 reduced
neutrophil infiltration in a model of carageenan-induced paw
edema; however, the edema profile was unchanged in the first
24 h post-carageenan in Gal-1 KO mice (Iqbal et al., 2011).
The enhanced neutrophil infiltration observed in Gal-1 KO in
the current study may indicate context specific actions for the
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FIGURE 3 | hrGal-1 administration following the peak of inflammation promotes neutrophil clearance. C57/Bl6 mice received zymosan (1 mg in 500 µl DPBS+/+
i.p.) at 0 h. At 8 h post-zymosan mice were administered hrGal-1 (10 µg) or vehicle (200 µl DPBS+/+) i.p. and peritoneal lavage performed at 24 h. Total cell counts
were performed (A). Flow cytometry was used to analyze the cell population for leukocyte subsets including neutrophils (7/4+Ly6G+) (B), inflammatory monocytes
(7/4+Ly6G−) (C), eosinophils (Siglec F+) (D), macrophages (F4/80+) (E), mature macrophages (F4/80+CD11bhigh) (F), and resolving macrophages
(F4/80+CD11blow) (G). Representative flow cytometry plots are inset for each subset. The neutrophil (Ly6G+) population was further assessed by AnnexinV (FITC)
and Zombie (NIR). Quadrant gating was applied to determine viable (AnxV−NIR−), early apoptotic (AnxV+NIR−), late apoptotic (AnxV+NIR+), and necrotic
(AnxV−NIR+) neutrophil populations. Results for the percentages of the neutrophil population within each of the quadrants are shown (H) with representative flow
cytometry plots inset for vehicle (left) and hrGal-1 (right) treated mice. Statistical analysis was performed using an unpaired t test (with each quadrant for apoptosis),
results are displayed as the mean ± SEM, and in all cases, significant results are considered as P < 0.05. n = 5–6 mice per group.
endogenous protein with increased neutrophil trafficking also
observed in Gal-1 KO mice in the colon in response to infection
with Citrobacter rodentium (Curciarello et al., 2014).
Inflammation induced by zymosan is reliant on the activation
of peritoneal macrophages via TLR2; evidence exists in the
literature that exogenous Gal-1 reduces pro-inflammatory
cytokine production from murine macrophages (Fredman et al.,
2012; Abebayehu et al., 2017) and skews toward an M2
(Barrionuevo et al., 2007) and pro-resolving phenotype (Fredman
et al., 2012). Additionally, macrophages from Gal-1 KO mice have
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FIGURE 4 | hrGal-1 administration following the peak of inflammation
shortened the resolution interval. Peritonitis was initiated in C57/Bl6 mice
using zymosan (1 mg in 500 µl DPBS+/+ given i.p.) and mice were treated
with hrGal-1 (10 µg) or vehicle (200 µl DPBS+/+) by i.p injection 8 h
post-zymosan. Peritoneal lavages were performed at 8, 24, and 48 h. Total
cell counts were performed and flow cytometry was used to quantify
neutrophil (7/4+Ly6G+) numbers. Resolution indices were calculated by
monitoring the maximum peritoneal neutrophil number (Tmax), when neutrophil
numbers declined by 50% (T50) and the resolution interval (Ri), the time from
Tmax to T50. n = 5–6 mice per group.
been shown to have enhanced expression of MHCII (Barrionuevo
et al., 2007). We have seen increased levels of pro-inflammatory
mediators in the early recruitment phase of the inflammatory
response in Gal-1 KO mice despite reduced macrophage numbers
in the peritoneal cavity, which may be suggestive of a heightened
pro-inflammatory response in macrophages in the absence of
Gal-1. To the best of our knowledge, a full characterization of
Gal-1 KO macrophage phenotype has not been performed and
the exact role of endogenous Gal-1 in macrophages still requires
full characterization.
While significantly more neutrophils were found within the
peritoneal cavity of Gal-1 KO mice at 6 h, this difference was
lost at 24 h suggesting that clearance might be enhanced in
these mice. Assessment of apoptosis and efferocytosis at this
time point showed no differences in the percentage of cells
undergoing either process (data not shown). It is feasible that
the apoptotic/efferocytic process is faster or earlier in Gal-1 KO
mice, or alternatively these results may simply be a reflection
of the efficiency of the resolution process and the ability of
the system to regain homeostasis. Exogenous Gal-1 has been
demonstrated to enhance macrophage phagocytosis of sheep red
blood cells in vitro; however, interestingly Gal-1 KO macrophages
also phagocytosed more effectively than WT cells when cultured
ex vivo (Barrionuevo et al., 2007). More recently, Gal-1 was
shown to induce efferocytic satiation in a model of zymosan-
induced peritonitis which is linked to early departure of these
macrophages from the resolving cavity. Surprisingly, although
Gal-1 is thought to enhance macrophage infiltration into the
resolving peritoneum (Gil et al., 2006; Malik et al., 2009), we did
not see a reduction in macrophage numbers in the peritoneal
cavity of Gal-1 KO animals, in fact the adverse was evidenced.
This may be in response to the increased neutrophil infiltrate
observed in these mice. These findings propose a divergence in
the roles of endogenous and exogenous Gal-1 and thus further
work is required to fully understand its role in efferocytosis.
There are several studies describing the ability of hrGal-
1 to inhibit neutrophil trafficking both in vitro and in vivo;
however, its effects on neutrophil clearance have not, to the
best of our knowledge been assessed in vivo. Importantly, in
this experimental setup, we determined neutrophil numbers in
response to exogenous Gal-1 administration after the peak of
inflammation (at a time point that should not affect neutrophil
recruitment) in order to assess neutrophil clearance. In vitro
studies from Stowell et al. (2009, 2007) describe the ability of Gal-
1 to induce exposure of the “eat me” signal PS on the surface of
neutrophils. Interestingly, PS exposure normally occurs as part
of the early stages of apoptosis; however, Gal-1 was not found
to induce apoptosis in their studies, rather it was proposed that
Gal-1-induced PS exposure is a mechanism to drive clearance
of neutrophils in the absence of apoptosis. Here, we detected
increased numbers of early apoptotic neutrophils within the
peritoneal cavities of mice treated with hrGal-1. While it was
not possible to determine whether these cells progressed through
the apoptotic process presumably due to the rapid clearance of
PS expressing cells in vivo, we did uncover a pro-apoptotic role
for Gal-1 when assessing the stages of apoptosis ex vivo. Further
studies are required to elucidate the mechanisms behind this
pro-apoptotic effect of Gal-1.
In support of the rapid engulfment of PS exposing neutrophils
in this model the lower numbers of resolving macrophages
detected 16 h post Gal-1 administration is suggestive of their
quick retreat to the lymphatics. Findings by Rostoker et al.
demonstrated that hrGal-1 treatment converts macrophages
from a CD11bhigh to a CD11blow phenotype during resolution.
The shift toward a resolving phenotype could be a direct response
to the increased numbers of early apoptotic neutrophils that we
report within our study. As hrGal-1 increases PS exposure on
neutrophils, an action that has been linked to enhanced clearance
(Stowell et al., 2009), this “eat me” signal might stimulate the
macrophage phenotypic switch to better enable clearance of these
cells. We propose that hrGal-1 treated mice undergo macrophage
phenotype switching sooner as a result of the increased apoptotic
neutrophils present in the cavity and the requirement of their
clearance. We hypothesize that the consequence of the more
rapid engulfment of apoptotic neutrophils is that resolving
macrophages in hrGal-1 treated mice reach efferocytic satiation
sooner and thus depart the cavity more swiftly.
There is evidence in the literature that Gal-1 can induce
apoptosis of human synovial fluid neutrophils from rheumatoid
arthritis patients (Cedeno-Laurent et al., 2010), which may
indicate a divergence between the effects of Gal-1 on neutrophils
in the periphery versus those that have trafficked to the
inflammatory site. Neutrophils that have trafficked to the
inflammatory site are known to express a different repertoire
of receptors (Hartl et al., 2008) and it is likely that upon
transmigration, Gal-1 is able to bind to a newly expressed
receptor on the cell surface. This also correlates with studies
indicating increased galectin binding to activated neutrophils and
importantly for this study on neutrophils that have trafficked
to the inflammatory site (Almkvist et al., 2002). Furthermore,
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the glycosylation status of neutrophils is modulated upon
transmigration, particularly with respect to sialic acid residues
(Cross et al., 2003). Sialic acid capping of glycoproteins negatively
impacts Gal-1 binding (Toscano et al., 2007), thus a reduction
in terminal sialic acids, through the action of sialidases, may
also permit the increased binding of Gal-1 to neutrophils post-
transmigration. The effects of galectins are indeed highly complex
and vary depending on local concentration, intracellular or
extracellular localization, or differentiation status of the target
cell, which may account for effects on neutrophils in the
periphery as well as in tissue.
The reduction in the resolution interval in response to Gal-
1 in this model provides further indication that the protein
augments the transition from inflammation to resolution. Gal-
1 administration at the 8 h time point reduced the resolution
interval from 39 to 14 h, suggesting that Gal-1 has pro-resolving
properties that may be of therapeutic utility. While native Gal-
1 is susceptible to oxidation, which can negatively impact its
activity, the form utilized in this study has been modified to
prevent oxidation and extend the half-life of the protein (Nishi
et al., 2008) suggesting that modified forms of the protein may
be therapeutically advantageous. However, due to the complexity
of galectin biology, a further understanding of their mechanism
of action is required before galectin-based therapeutics can be
utilized clinically.
Collectively, our findings confirm an anti-trafficking role for
endogenous Gal-1 and indicate a pro-apoptotic function for the
exogenous soluble protein. The clearance of apoptotic cells is a
fundamental process following cell damage, aging, and trafficking
of leukocytes to an inflammatory site and hence is critical for
the resolution of inflammation and preservation of self-tolerance.
Our results enhance our understanding of the role of Gal-1
in resolution and sheds light on the promising nature of this
protein for the development of a new class of therapeutics that
activate resolution.
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FIGURE S1 | Inflammatory mediators are increased in the absence of Gal-1. Mice
received zymosan (1 mg in 500 µl DPBS+/+ i.p.) and peritoneal lavage was
performed at 2 h. Exudate was assessed for total cell counts (A) and the number
of neutrophils (7/4+Ly6G+) (B), eosinophils (Siglec F+) (C), inflammatory
monocytes (7/4+Ly6G−) (D), mature macrophages (F4/80+CD11bhigh) (E), and
resolving macrophages (F4/80+CD11blow) (F) were identified by flow cytometry.
The cell free supernatant was collected from 1ml of peritoneal exudate and
concentrations of analytes measured by ELISA. Results for the concentrations of
cell recruitment chemokines CCL2 (MCP-1) (G), CCL3 (MIP-1-α) (H), and CXCL-1
(KC) (I) are shown. Levels of inflammatory cytokines TNF-α (J) and IL-6 (K) are
shown for both genotypes, as well as the growth factor VEGF (L). Statistical
analysis was performed using an unpaired t-test and significant results considered
as P < 0.05, n = 7–8 mice per group.
FIGURE S2 | Ex vivo neutrophil apoptosis is increased with hrGal-1. C57/Bl6 mice
received zymosan (1 mg in 500 µl DPBS+/+ i.p.) at 0 h. At 2 h post-zymosan
mice were administered hrGal-1 (10 µg) or vehicle (200 µl DPBS−/−) and
peritoneal lavage performed at 6 h to collect leukocytes from the cavity. Peritoneal
exudate (1 ml) cells were resuspended in RPMI–1640 Medium + 0.5% BSA and
incubated (20 h). Flow cytometry was used to select the neutrophil (Ly6G+)
population which was further assessed by AnnexinV (FITC) and Zombie (NIR).
Quadrant gating was applied to determine viable (AnxV−NIR−), early apoptotic
(AnxV+NIR−), late apoptotic (AnxV+NIR+), and necrotic (AnxV−NIR+) neutrophil
populations in vehicle (A) and hrGal-1 (B) treated mice. Results for the
percentages of the neutrophil population within each of the quadrants are
shown (C). Statistical analysis was performed using an unpaired t-test (with each
quadrant for apoptosis), results are displayed as the mean ± SEM, and in all
cases, significant results are considered as P < 0.05. n = 6–7 mice per group.
TABLE S1 | Leukocyte numbers in 48 h peritoneal exudate with hrGal-1
administered following the peak of inflammation. Peritonitis was initiated in
C57/Bl6 mice using zymosan (1 mg, i.p.) and mice were treated with hrGal-1
(10 µg) or vehicle (200 µl DPBS−/−) 8 h post-zymosan and peritoneal lavage was
performed at 48 h. Total cell counts were performed and the number of
neutrophils (7/4+Ly6G+), inflammatory monocytes (7/4+Ly6G−), eosinophils
(SiglecF+), macrophages (F4/80+), mature macrophages (F4/80+CD11bhigh), and
resolving macrophages (F4/80+CD11blow) were identified by flow cytometry.
Statistical analysis was performed using an unpaired t-test. Results displayed as
the mean ± SEM; in all cases, significant results were considered as P < 0.05.
n = 5 mice per group.
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